BioPharma Credit PLC STATEMENT RE IMMUNOGEN, INC. (3667V)
2023年12月1日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMBPCR
RNS Number : 3667V
BioPharma Credit PLC
01 December 2023
1 December 2023
BIOPHARMA CREDIT PLC
(THE "COMPANY")
STATEMENT RE ImmunoGen, Inc.
Pharmakon Advisors, LP, the investment manager of the Company,
notes the announcement released Thursday 30 November 2023 by AbbVie
Inc. ("AbbVie") regarding the definitive agreement pursuant to
which AbbVie will acquire ImmunoGen, Inc. ("IMGN") for a total
equity value of approximately US$10.1 billion (the "Transaction").
AbbVie and IMGN currently anticipate that the Transaction will
close in the middle of 2024.
The Company announced on 11 April 2023 an investment in a senior
secured loan to IMGN of up to US$62.5 million in up to two
tranches. As of today, the Company had funded the first tranche
representing a US$37.5 million investment. The loan is expected to
be prepaid upon the closing of the Transaction. Pursuant to the
senior secured loan agreement, in connection with the Transaction
and the repayment of outstanding principal, the Company is expected
to receive a make-whole payment for the remainder of the three-year
make-whole period along with a prepayment premium of 3%, in each
case with respect to the principal repaid. For illustrative
purposes, if the Transaction were to close on 30 June 2024, the
Company would be expected to receive approximately US$14.5 million
in prepayment and make-whole fees.
Enquiries
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0) 20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors
BioPharma Credit PLC is London's only specialist debt investor
to the life sciences industry and joined the LSE in March 2017.
BioPharma Credit PLC seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry.
BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other
cash flows derived from the sales of approved life sciences
products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STRUPGPCPUPWUQG
(END) Dow Jones Newswires
December 01, 2023 02:00 ET (07:00 GMT)
Biopharma Credit (LSE:BPCP)
過去 株価チャート
から 11 2024 まで 12 2024
Biopharma Credit (LSE:BPCP)
過去 株価チャート
から 12 2023 まで 12 2024